Literature DB >> 8726023

Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

N Mor1, B Simon, L Heifets.   

Abstract

Inhibitory and bactericidal activities of KRM-1648 were determined against Mycobacterium tuberculosis and M. avium residing in human monocyte-derived macrophages and extracellular M. tuberculosis and M. avium. MICs and MBCs of KRM-1648 against intracellular and extracellular bacteria were substantially lower than those of rifampin. The MICs and MBCs of either drug against the intracellular bacteria were only twofold lower than or equal to the values found for extracellular bacteria. The prolonged effect of KRM-1648 found in this study is probably associated with high ratios of intracellular accumulation, which were 50- to 100-fold higher than that found for rifampin. Further studies on intracellular distribution of KRM-1648 and on the sites of actual interaction between the drug and bacteria residing in macrophages are necessary, as well as evaluation of combined effects of KRM-1648 with other drugs in long-term macrophage culture experiments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726023      PMCID: PMC163353          DOI: 10.1128/AAC.40.6.1482

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-06

2.  Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice.

Authors:  H Tomioka; H Saito; K Sato; T Yamane; K Yamashita; K Hosoe; K Fujii; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

3.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

Authors:  N Mor; J Vanderkolk; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.

Authors:  H Saito; H Tomioka; K Sato; S Kawahara; T Hidaka; S Dekio
Journal:  Tuber Lung Dis       Date:  1995-02

5.  In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method.

Authors:  H Tomioka; H Saito; K Fujii; K Sato; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

6.  In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli.

Authors:  J Luna-Herrera; M V Reddy; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.

Authors:  J M Dickinson; D A Mitchison
Journal:  Tubercle       Date:  1987-09

8.  Methods for determining concentrations of antimicrobial agents in human monocytes.

Authors:  N Mor; B Simon; L Heifets
Journal:  J Chemother       Date:  1995-06       Impact factor: 1.714

9.  In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis.

Authors:  T Hirata; H Saito; H Tomioka; K Sato; J Jidoi; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

10.  Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy; W Kanes
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more
  4 in total

1.  Antimycobacterial agent based on mRNA encoding human beta-defensin 2 enables primary macrophages to restrict growth of Mycobacterium tuberculosis.

Authors:  K O Kisich; L Heifets; M Higgins; G Diamond
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Effects of benzoxazinorifamycin KRM-1648 on cytokine production at sites of Mycobacterium avium complex infection induced in mice.

Authors:  H Tomioka; K Sato; T Shimizu; C Sano; T Akaki; H Saito; K Fujii; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 3.  Caseum: a Niche for Mycobacterium tuberculosis Drug-Tolerant Persisters.

Authors:  Jansy P Sarathy; Véronique Dartois
Journal:  Clin Microbiol Rev       Date:  2020-04-01       Impact factor: 26.132

4.  Culture-Free Enumeration of Mycobacterium tuberculosis in Mouse Tissues Using the Molecular Bacterial Load Assay for Preclinical Drug Development.

Authors:  Dimitrios Evangelopoulos; Carolyn M Shoen; Isobella Honeyborne; Simon Clark; Ann Williams; Galina V Mukamolova; Michael H Cynamon; Timothy D McHugh
Journal:  Microorganisms       Date:  2022-02-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.